New liver drug tested for heart risks in healthy people
Knowledge-focused
Completed
This study checked whether a single dose of hydronidone, a drug being developed for liver scarring (hepatic fibrosis), affects the heart's electrical activity (QTc interval). 48 healthy Chinese adults took either a low, medium, or high dose of the drug or a placebo. The main goal…
Phase: PHASE1 • Sponsor: Beijing Continent Pharmaceutical Co, Ltd. • Aim: Knowledge-focused
Last updated May 11, 2026 20:40 UTC